公开(公告)号：US09593309B2

公开(公告)日：2017-03-14

申请号：US14707564

申请日：2015-05-08

Applicant: InGeneron, Inc. ,  ArthroDynamic Technologies, Animal Health Division, Inc.

Inventor： Michael Coleman ,  Ivone Bruno ,  Rudy Martinez ,  Amir Sanchez ,  Eckhard Alt ,  Frank D. Marcum ,  Paul Shealy

IPC: C12N5/0775 ,  A01N1/02 ,  C12N5/00 ,  A61K31/737 ,  A61K35/28

CPC classification number: C12N5/0667 ,  A01N1/0221 ,  A01N1/0284 ,  A61K31/737 ,  A61K35/28 ,  C12N5/0018 ,  C12N2501/90 ,  C12N2501/905 ,  C12N2533/70 ,  C12N2533/80 ,  C12N2539/00 ,  A61K2300/00

Abstract: A culture media, media supplement, or soluble matrix for cryopreservation or enhanced regenerative cell growth in culture and maintenance of multi-lineage differentiation potentiation. The inventive culture media, media supplement, or soluble matrix comprises a GAG composition comprising a sulfated GAG, such as chondroitin sulfate. A soluble matrix, a cell administration package or kit comprising the soluble matrix and a device for cell administration, and a method of use thereof, for administration of regenerative cells for treating a joint disease or other weakened or damaged tissue comprising the specified GAG compositions are further provided.

Abstract translation: 培养基，培养基补充剂或可溶性基质用于冷冻保存或增强培养中的再生细胞生长并维持多系分化增强。 本发明的培养基，培养基补充剂或可溶性基质包括含有硫酸化GAG的GAG组合物，例如硫酸软骨素。 可溶性基质，包含可溶性基质和细胞给药装置的细胞给药包或试剂盒及其使用方法，用于施用用于治疗关节疾病的再生细胞或包含特定GAG组合物的其他弱化或损伤的组织， 进一步提供。

公开(公告)号：US20170015977A1

公开(公告)日：2017-01-19

申请号：US15278152

申请日：2016-09-28

Applicant: Swiss Stem Cell Foundation

Inventor： Gianni Soldati ,  Tiziano Tallone

IPC: C12N5/0775

CPC classification number: C12N5/0667 ,  C12N2501/70 ,  C12N2501/734 ,  C12N2509/00 ,  C12N2527/00

Abstract: A highly safe procedure for the preparation of purified stem cell fractions of lipid origin is herein described, in which the use of a specially designed single collecting device, reduces the number of passages and manipulations undergone by stem cell-containing material, reducing to a minimum the risks of contamination, material loss, and inadvertent exchange of samples, and further simplifying the interface and cooperation between personnel recovering the raw material and those expert in stem cell isolation.

Abstract translation: 本文描述了用于制备脂质来源的纯化干细胞级分的高度安全的方法，其中使用特别设计的单一收集装置减少了通过含干细胞的材料经历的传代次数和操作，减少到最小 污染，材料损失和无意间交换样品的风险，进一步简化了恢复原材料的人员与干细胞隔离专家之间的界面和合作。

公开(公告)号：US20170009211A1

公开(公告)日：2017-01-12

申请号：US15278102

申请日：2016-09-28

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran HORNSTEIN ,  Sharon KREDO-RUSSO

IPC: C12N5/071 ,  C07K14/62 ,  C12N15/113

CPC classification number: C12N5/0676 ,  A61K31/7088 ,  A61K35/39 ,  C07K14/62 ,  C12N5/0662 ,  C12N5/0663 ,  C12N5/0664 ,  C12N5/0665 ,  C12N5/0666 ,  C12N5/0667 ,  C12N5/0668 ,  C12N15/113 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/11 ,  C12N2501/65

Abstract: A method of ex-vivo increasing insulin content in beta cells or stem cells is disclosed. The method comprising contacting the beta cells or stem cells with an agent for downregulating an activity or expression of miR-7, thereby increasing the insulin content in the beta cells or stem cells.

Abstract translation: 公开了一种离体增加β细胞或干细胞中胰岛素含量的方法。 该方法包括使β细胞或干细胞与用于下调miR-7的活性或表达的试剂接触，从而增加β细胞或干细胞中的胰岛素含量。

公开(公告)号：US20170000724A1

公开(公告)日：2017-01-05

申请号：US15266951

申请日：2016-09-15

Applicant: BioRegenerative Sciences, Inc.

Inventor： Greg Maguire

IPC: A61K8/98 ,  A61K35/33 ,  A61Q7/00 ,  A61K35/28

CPC classification number: A61K8/981 ,  A61K35/12 ,  A61K35/28 ,  A61K35/33 ,  A61K2800/74 ,  A61Q7/00 ,  C12N5/0628 ,  C12N5/0656 ,  C12N5/0667

Abstract: Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (SRM's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and SRM's can be derived from one or more distinct cell lines. The SRM's can further include one or more mucins, cytokines, or growth factors. Exemplary formulations include stem cells and SRMs derived from epithelial stem cells, corneal limbal stem cells, and fibroblasts. Other compositions and methods for formulation thereof are described.

Abstract translation: 用于治疗各种组织疾病的组合物包括用纤维素材料或其它增稠剂悬浮在水溶液中的干细胞和干细胞释放分子（SRM）。 干细胞和SRM可以衍生自一个或多个不同的细胞系。 SRM可以进一步包括一种或多种粘蛋白，细胞因子或生长因子。 示例性制剂包括源自上皮干细胞，角膜缘干细胞和成纤维细胞的干细胞和SRM。 其他组合物及其配制方法进行了描述。

公开(公告)号：US09518251B2

公开(公告)日：2016-12-13

申请号：US15074490

申请日：2016-03-18

Applicant: GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.

Inventor： Shinn-Zong Lin ,  Horng-Jyh Harn ,  Ru-Huei Fu ,  Shih-Ping Liu ,  Po-Cheng Lin ,  Ming-Hsi Chuang

IPC: C12N5/00 ,  C12N5/02 ,  C12N5/0775 ,  A61K35/545 ,  A61K35/28

CPC classification number: A61K35/28 ,  A61K31/365 ,  A61K35/545 ,  C12N5/0667 ,  C12N2501/40 ,  C12N2501/999

Abstract: A method for enhancing the therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises pre-treating the stem cells with ligustilide to increase the expression of differentiation-promoting genes in the stem cells, increase the expression of homing-promoting genes in the stem cells, and/or decrease the expression of inflammatory genes in the stem cells, wherein the treatment is conducted in a culture medium of the stem cell.

Abstract translation: 提供了增强干细胞对自身免疫性疾病，心血管疾病和/或血液疾病的治疗效果的方法。 该方法包括用ligustilide预处理干细胞，以增加干细胞中分化促进基因的表达，增加干细胞中归巢促进基因的表达，和/或减少干细胞中炎症基因的表达 细胞，其中处理在干细胞的培养基中进行。

公开(公告)号：US09504716B2

公开(公告)日：2016-11-29

申请号：US12853110

申请日：2010-08-09

Applicant: Marc H. Hedrick ,  John K. Fraser ,  Susan Lynn Riley ,  Ronda Elizabeth Schreiber

Inventor： Marc H. Hedrick ,  John K. Fraser ,  Susan Lynn Riley ,  Ronda Elizabeth Schreiber

IPC: C12N5/00 ,  A61K35/28 ,  A61L27/38 ,  A61L27/52 ,  A61L27/56 ,  C12N5/0775 ,  A61L27/18 ,  A61L27/36 ,  A61L27/54

CPC classification number: A61K35/28 ,  A61L27/18 ,  A61L27/3608 ,  A61L27/365 ,  A61L27/3654 ,  A61L27/3691 ,  A61L27/3834 ,  A61L27/3847 ,  A61L27/3852 ,  A61L27/3895 ,  A61L27/52 ,  A61L27/54 ,  A61L27/56 ,  A61L2300/40 ,  A61L2300/412 ,  A61L2300/64 ,  A61L2400/06 ,  A61L2430/02 ,  A61L2430/06 ,  A61L2430/40 ,  C12N5/0667

Abstract: Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit.

Abstract translation: 存在于脂肪组织中的再生细胞用于治疗患者，包括肌肉骨骼疾病或病症的患者。 治疗患者的方法包括加工脂肪组织以将从脂肪组织获得的浓缩量的再生细胞输送给患者。 所述方法可以在封闭系统中实施，使得干细胞在施用于患者之前不暴露于外部环境。 因此，在优选的方法中，存在于脂肪组织中的再生细胞与用于促进，产生或支持治疗性肌肉骨骼益处所必需的这种添加剂一起直接放置在受体中。

公开(公告)号：US20160310540A1

公开(公告)日：2016-10-27

申请号：US15203684

申请日：2016-07-06

Applicant: CYTORI THERAPEUTICS, INC.

Inventor： John K. Fraser ,  Marc H. Hedrick ,  Eric Daniels

IPC: A61K35/35 ,  A61K9/00 ,  A61K45/06 ,  C12N5/0775 ,  A61L15/40 ,  A61L27/54 ,  A61L27/36 ,  A61K35/44 ,  A61L15/44

CPC classification number: A61K35/28 ,  A61K9/0014 ,  A61K35/12 ,  A61K35/35 ,  A61K35/36 ,  A61K35/44 ,  A61K38/1866 ,  A61K45/06 ,  A61L15/40 ,  A61L15/44 ,  A61L27/3604 ,  A61L27/3834 ,  A61L27/54 ,  A61L27/56 ,  A61L2300/412 ,  A61L2300/64 ,  C12N5/0667 ,  C12N5/069 ,  C12N2506/1384 ,  A61K2300/00

Abstract: Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.

Abstract translation: 存在于脂肪组织中的细胞用于促进患者的伤口愈合。 治疗患者的方法包括加工脂肪组织以将从脂肪组织获得的浓缩量的再生细胞输送给患者。 所述方法可以在封闭系统中实施，使得再生细胞在施用于患者之前不暴露于外部环境。 因此，在优选的方法中，存在于脂肪组织中的细胞与促进，产生或支持治疗益处所必需的这种添加剂一起直接放置在受体中。

公开(公告)号：US20160289640A1

公开(公告)日：2016-10-06

申请号：US14912391

申请日：2014-08-14

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Chul Woo YANG ,  Mi-La CHO ,  Sung-Hwan PARK ,  Eun Kyung KIM ,  Byung Ha CHUNG ,  Kyoung-Woon KIM ,  Seon-Yeong LEE ,  Sung-Hee LEE ,  Eun Ji YANG ,  Jeong-hee JEONG ,  Min Jung PARK ,  Seok-Jung KIM ,  Eun-Jung LEE ,  Su-Jin MOON

IPC: C12N5/0775 ,  A61K38/17 ,  A61K35/28 ,  C07K14/715

CPC classification number: C12N5/0667 ,  A61K35/28 ,  A61K38/177 ,  C07K14/7158 ,  C12N5/0665 ,  C12N2501/04

Abstract: The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-β and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII. If this cell is used as a cell therapy in individuals having immune disorders, it is possible to effectively treat immune disorders.

Abstract translation: 本发明涉及具有免疫调节活性的间充质干细胞及其制备方法，更具体地涉及：具有免疫调节活性的雷帕霉素治疗的间充质干细胞，其表达任何一种或多种选自以下的细胞表面因子： CCR1，CCR2，CCR3，CCR4，CCR7，CCR9和CXCR4; 包含间充质干细胞用于预防或治疗免疫疾病的细胞疗法组合物; 以及具有免疫调节活性的间充质干细胞的制备方法。 根据本发明的具有免疫调节活性的雷帕霉素处理的间充质干细胞具有增加作为具有免疫调节活性的因子的IDO，TGF-β和IL-10的表达，具有降低的磷酸化mTOR，Rictor和Ractor的表达， mTOR的信号转导因子，并且在自噬诱导物Beclin1，ATG5，ATG7，LC3I或LCII的细胞中表达增加。 如果该细胞在具有免疫障碍的个体中用作细胞疗法，则有可能有效治疗免疫疾病。

公开(公告)号：US09453202B2

公开(公告)日：2016-09-27

申请号：US10575063

申请日：2004-10-07

Applicant: Robert J Harman, Jr. ,  Theodore T Sand

Inventor： Robert J Harman, Jr. ,  Theodore T Sand

IPC: A01N63/00 ,  C12N5/0775 ,  A61K35/12

CPC classification number: A61K35/35 ,  A61K35/12 ,  C12N5/0667 ,  C12N2509/00 ,  C12N2509/10

Abstract: The present invention provides novel stem cell compositions having significant therapeutic and practical advantages, as well as methods of preparing and using such compositions for the treatment and prevention of injury and disease in patients. The invention may be applied to stem cell populations isolated from a wide variety of animals, including humans, and tissues. In particular applications, the invention is used to prepare a stem cell composition from a collagen-based tissue, such as adipose tissue, isolated from a patient, and the stem cell composition is subsequently provided to a site of actual or potential injury in the patient. The invention further includes related kits comprising the stem cell compositions, which are remarkably stable and retain viability and efficacy during storage and shipment.

Abstract translation: 本发明提供了具有显着治疗和实践优点的新型干细胞组合物，以及制备和使用这些组合物用于治疗和预防患者的损伤和疾病的方法。 本发明可以应用于从包括人和组织在内的各种动物分离的干细胞群体。 在具体应用中，本发明用于从患者分离的基于胶原的组织（例如脂肪组织）制备干细胞组合物，随后将干细胞组合物提供给患者的实际或潜在损伤的部位 。 本发明还包括相关的试剂盒，其包含干细胞组合物，其在储存和运输过程中是显着稳定的并保持生存力和功效。

公开(公告)号：US20160250259A1

公开(公告)日：2016-09-01

申请号：US15147586

申请日：2016-05-05

Applicant: SpineSmith Partners, L.P.

Inventor： Kevin Dunworth ,  Richard J. Kana ,  Theodore Sand ,  Matthew Murphy

IPC: A61K35/28 ,  A61K35/14

CPC classification number: A61K35/28 ,  A61K35/14 ,  A61K35/35 ,  C12N5/0663 ,  C12N5/0667 ,  C12N2502/1358 ,  C12N2502/1382 ,  A61K2300/00

Abstract: The invention is directed to a therapeutic composition that includes a first cell preparation that includes isolated stromal cells of a first type and a second cell preparation that includes isolated stromal cells of a second type. The first and second cell preparations may include cultured cells. The stromal cells may include adipose stromal cells and bone marrow derived stromal cells. The therapeutic composition may include a blood component that includes one or more of platelet-poor plasma, concentrated platelet-poor plasma, platelet-rich plasma, and whole blood.

Abstract translation: 本发明涉及治疗组合物，其包括第一细胞制剂，其包括第一类型的分离的基质细胞和包含第二类型的分离的基质细胞的第二细胞制剂。 第一和第二细胞制剂可以包括培养的细胞。 基质细胞可以包括脂肪基质细胞和骨髓来源的基质细胞。 治疗组合物可以包括血液成分，其包含贫血小血浆，浓缩血小板血浆，富血小板血浆和全血中的一种或多种。